
	Three Months Ended				Six Months Ended
	September 26, 2026		September 27, 2025		September 26, 2026		September 27, 2025

	(Dollars and Shares in Thousands, Except Per Share)
Net income	$	46,305	$	38,684	$	79,315	$	72,715

Basic weighted average shares outstanding	45,500		47,590		45,430		47,850
Dilutive net effect of common stock equivalents	963		74		654		159
Diluted weighted average shares	46,463		47,664		46,084		48,009

Net income per share
Basic	$	1.02	$	0.81	$	1.75	$	1.52
Diluted	$	1.00	$	0.81	$	1.72	$	1.51

Anti-dilutive shares excluded from the calculation	606		1,134		743		1,041

Basic earnings per share is calculated using the Company’s weighted average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company’s common shares has been less than the applicable initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion values of the convertible senior notes.

In April 2025, the Board approved a new three-year share repurchase program authorizing the repurchase of up to $500.0 million of Haemonetics common stock, based on market conditions, through April 2028. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

During fiscal 2026, the Company repurchased 3,009,834 shares for $175.0 million at an average price per share upon settlement of $58.14. As of September 26, 2026, the total remaining authorization for repurchases of the Company's common stock under the 2025 share repurchase program was $325.0 million.